CTKB (Cytek Biosciences) Cash per Share: $2.03 (As of Mar. 2026)

What is Cytek Biosciences Cash per Share?

Cytek Biosciences CTKB +0.54% 71 Cash per Share is $2.03 as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Cytek Biosciences's Cash per Share for the quarter that ended in Mar. 2026 was $2.03.

Cytek Biosciences (NAS:CTKB) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Cytek Biosciences Cash per Share Related Terms

Cytek Biosciences Cash per Share Historical Data

* Premium members only.

The historical data trend for Cytek Biosciences's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytek Biosciences Cash per Share Chart

Cytek Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

2.73

2.52

2.01

2.15

2.03

Cytek Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															2.08	2.06	2.05	2.03	2.03

71GF Score

Cytek Biosciences Inc CTKB

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cytek Biosciences Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Cytek Biosciences's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	261.529	/	128.6
	=	2.03

Cytek Biosciences's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	262.225	/	129.1
	=	2.03

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $2.03 mean?

Cytek Biosciences (CTKB) has a Cash per Share of $2.03 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Cytek Biosciences and its competitors.

Is Cytek Biosciences' Cash per Share too high?

Cytek Biosciences' current Cash per Share is $2.03. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Cytek Biosciences' Cash per Share compare to CERS and NPCE?

Cytek Biosciences' Cash per Share of $2.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Medical Devices & Instruments company?

A good Cash per Share depends on the Medical Devices & Instruments industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Cytek Biosciences and its competitors. Cytek Biosciences's current Cash per Share is $2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cytek Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.63 — trading 20.6% below its estimated fair value. The current Cash per Share is $2.03. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Cash per Share is $2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.63 is trading 20.6% below its estimated GF Value™ of $5.83. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

Cash per Share: $2.03
GF Value™: $5.83 vs. price of $4.63 (20.6% below fair value)
GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CERS NPCE CLPT KIDS PACB BVS MOBI SSII SI TCMD ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges 8EQ:Germany

Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538

Website https://www.cytekbio.com

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

71GF Score

Get the complete analysis for CTKB

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63

Price

$5.83

GF Value

View CTKB Analysis

See Cash per Share data for all stocks →